drugset / Trial / NCT04184466

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects

NCT04184466

Completed 26 enrolled Geropharm
RandomizedCrossoverSingle-blindBasic science

Summary

Pharmacokinetics and pharmacodynamics study of 2 formulations of insulin aspart (Insulin Aspart GEROPHARM vers. NovoRapid® Penfill® Novo Nordisk)

Timeline

Start
2018-10-18
Primary completion
2018-12-19
Completion
2018-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic 0.3 iu/kg Subcutaneous

Indications

No indication recorded.